Reboot, Rethink

Bristol-Myers, Roche, Novartis, AZ: Big Pharma’s shrinking club in India

Pharma MNCs came in bunches, realised India is not quite their cup of tea and are now rearranging their decks. What we have are layoffs, marketing alliances, and a shrewd post-consolidation wait-and-watch

12/11/18

Seema Singh

Indian pharma grew at 6.3% in FY18, the slowest in over a decade. Compared to regulated markets, it’s still high growth rate for Big Pharma. But in value terms, India offers chump change

 

Global headwinds have forced them to relook at India, dividing the pack into long- and shortermists

 

Quiet layoffs, portfolio pruning, and unique marketing alliances are in the order

 

Volume game players are angling for Ayushman Bharat, hoping for a  Chinese success story replay where state insurance has given them high double-digit growth. Is that possible?

 

jeroen-wehkamp-668832-unsplash.jpg

Want to read a free 200 word summary?

Create an account

Pharma MNCs came in bunches, realised India is not quite their cup of tea, and are now rearranging their decks. What we have are layoffs, marketing alliances, and a shrewd post-consolidation wait-and-watch

To access this post, you must purchase Monthly Recurring, Quarterly or Weekly Product.

Read the full story. Subscribe to Premium.

Or subscribe. Why? Let us explain.

Subscribe now

Already Registered?

Related stories

More stories in /Analysis & /Healthcare

See all in Healthcare, Reportage & Startups

This story is for subscribers only.
Subscribe or Log In

Read the full story. Subscribe now.

Or subscribe. Why? Let us explain.

The selected story is available only for paid subscribers. Might want to change your mind!

Subscribe now

Already Registered? Login

Questions?

What is The Ken?

The Ken is a subscription-driven media site. We write one story a day (weekdays only). These stories have sharp, original insights on technology, business, science and healthcare from India.

Why do I have to sign up to read your stories?

Our stories are not free. Well, some select stories are. But, a significant part of what we write at The Ken is for subscribers only. We put in a lot of effort and resources in writing our stories and believe that you must pay for good journalism.
Hence, our three plans. 1) The annual membership
2) The free sign up
3) The recurring quarterly subscription

On journalism and why you should pay for it, if you haven’t already seen it, here’s a great explainer from John Oliver.

So, one must pay for journalism?

Yes.

How many stories will I get if I take an annual membership?

200+ stories.

And, in the free sign up?

Four stories every month.

Do I get a refund?

We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am not getting my daily emails. Do I have to whitelist emails from The Ken?

An added benefit of your subscription (free/paid) are the daily personalised emails. These emails, at times, might end up in your spam/junk folder due to emojis, attachments or images. In case you’re not receiving these emails, it might help to whitelist us. If the problem still persists, write to us at [email protected].

Why am I unable to access the archives?

Full and unrestricted access to our archives is a feature of our annual membership.

My payment is not going through, what can I do?

Please write to us at [email protected] detailing the payment error or queries.

See all FAQs

    See all results for Ken

    No results found for Ken.